<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03340610</url>
  </required_header>
  <id_info>
    <org_study_id>VGFTe-DME-1519</org_study_id>
    <nct_id>NCT03340610</nct_id>
  </id_info>
  <brief_title>IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab</brief_title>
  <acronym>ROTATED</acronym>
  <official_title>Intravitreal Alflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) After Treatment With Bevacizumab And Ranibizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeast Retina Center, Georgia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southeast Retina Center, Georgia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial.
      Study eyes will receive 5 required initial monthly Intravitreal Aflibercept (IAI) doses of 2
      mg followed by 2q8 IAI for a total of 52 weeks; only one study eye from each patient will be
      enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial.
      Study eyes will receive 5 required initial monthly IAI doses of 2 mg followed by 2q8 IAI for
      a total of 52 weeks; only one study eye from each patient will be enrolled.

      Starting at week 24, patients may be eligible to receive additional 2mg IAI (2q4) treatment
      if both of the following criteria is met and the investigator feels additional treatment
      would be beneficial:

        -  Loss of &gt;5 letters from baseline or best previously recorded best corrected visual
           acuity (BCVA)

        -  Presence of new or recurrent intraretinal fluid or subretinal fluid as assessed by SD
           OCT

      Starting at week 24, rescue therapy with macular laser photocoagulation may be administered
      if any the following criteria are met

        -  Loss of &gt; 15 letters from baseline or best previously recorded BCVA and loss of acuity
           felt to be secondary to Diabetic Macular Edema (DME) and not from other cause (i.e.,
           cataract, epiretinal membrane, vitreous hemorrhage, etc) and investigator feels patient
           would benefit from rescue therapy

        -  Increase in SD OCT CSF &gt; 100 um from baseline or best previously recorded SD OCT CSF and
           investigator feels patient would benefit from rescue therapy.

      Every 4 week visit will include ETDRS BCVA, IOP measurement, Slit lamp biomicroscopy,
      Indirect ophthalmoscopy, Heidelberg Spectralis SD-OCT and evaluation for systemic and ocular
      adverse events. Fundus Photography and Wide field Optos fluorescein angiography will be
      performed at baseline and at week 20and week 52.

      STUDY DURATION: Approximately 52 weeks to the end of the study. Primary endpoint will be
      evaluated at week 52.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">December 12, 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Macular Edema</measure>
    <time_frame>52 weeks from baseline</time_frame>
    <description>Reduction in macular edema measured as
Proportion of eyes with baseline SD OCT CST &gt;350 um demonstrating &gt;15% reduction at week 52 from baseline
Proportion of eyes that demonstrate SD OCT CST &lt;305um (males) and &lt;290 um (females) at week 52 from baseline</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Open Label Single Arm Trial</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Evaluating the efficacy of Alflibercept Injections in DME Following Treatment With Bevacizumab and Ranibizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alflibercept</intervention_name>
    <description>Intravitreal Injection</description>
    <arm_group_label>Open Label Single Arm Trial</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A patient must meet the following criteria to be eligible for inclusion in the study:

        1. Adults with Diabetes Mellitus 2. Documented history of ROTATE study completion (within 3
        months +/- 1 week of exit visit) 3. BCVA ETDRS visual acuity letter score 20/25-20/400 4.
        Thickening due to DME involving the center of the macula evident on clinical exam 5. DME on
        OCT at baseline (&gt;305 microns if male or &gt;290 microns if female) as assessed on Heidelberg
        Spectralis SD OCT 6. At least 30 days but less than 45 days since prior 0.3 mg ranibizumab
        injection 7. Willing and able to comply with clinic visits and study-related procedures 8.
        Provide signed HIPAA statement and informed consent prior to any study procedures

        -

        Exclusion Criteria:

        A patient who meets any of the following criteria will be excluded from the study:

          1. Macular edema considered to be due to a cause other than DME (ERM, Vein Occlusion,
             Postop CME, uveitis)

          2. History of PRP within 3 months prior to enrollment or anticipated need for PRP

          3. History of idiopathic or autoimmune uveitis in the study eye

          4. Cataract surgery in the study eye within 90 days of baseline

          5. Any intraocular surgery within 90 days of baseline

          6. Vitreomacular traction or epiretinal membrane in the study eye that is thought to
             affect vision

          7. Clinically significant pre-retinal fibrosis involving the macula in the study eye per
             investigator judgment

          8. Intraocular inflammation of trace or above in the study eye

          9. Evidence of active infection in either eye

         10. Uncontrolled glaucoma in the study eye defined as a pressure of &gt; 25 on maximal
             medical therapy.

         11. Concurrent disease in the study eye, other than DME, that could compromise VA, require
             medical or surgical intervention during the study or could confound interpretation of
             the results

         12. Ocular media of insufficient quality to obtain fundus and OCT images

         13. Current treatment for a serious systemic infection

         14. Administration of systemic anti-angiogenic agents within 180 days of screen

         15. History of yag capsulotomy within 1 month prior to enrollment

         16. Receipt of any treatment for DME, other than ranibizumab 0.3 mg, in the study eye at
             any time in the past 3 months following ROTATE study exit, (such as focal/grid macular
             photocoagulation, intravitreal or peribulbar corticosteroids or other anti-VEGF agents
             such as Macugen, 2 mg IAI,, 0.5 mg ranibizumab, or intravitreal bevacizumab)

         17. Any women who are pregnant, breast-feeding, or attempting to become pregnant

         18. Sexually active men* or women of childbearing potential** who are unwilling to
             practice adequate contraception during the study (adequate contraceptive measures
             include stable use of oral contraceptives or other prescription pharmaceutical
             contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device
             [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or
             jelly, or diaphragm plus contraceptive sponge, foam, or jelly)

               -  Contraception is not required for men with documented vasectomy. **Postmenopausal
                  women must be amenorrheic for at least 12 months in order not to be considered of
                  child bearing potential. Pregnancy testing and contraception are not required for
                  women with documented hysterectomy or tubal ligation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis M Marcus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southeast Retina Center, PC.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southeast Retina Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <results_first_submitted>April 9, 2019</results_first_submitted>
  <results_first_submitted_qc>April 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2019</results_first_posted>
  <last_update_submitted>May 8, 2019</last_update_submitted>
  <last_update_submitted_qc>May 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03340610/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phase 4 Prospective, Nonrandomized, Open Label, Interventional</title>
          <description>Evaluating the efficacy of Alflibercept Injections in DME Following Treatment With Bevacizumab and Ranibizumab
Alflibercept: Intravitreal Injection
Study eyes will receive 5 required initial monthly IAI doses of 2 mg followed by 2q8 IAI for a total of 52 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open Label Single Arm Trial</title>
          <description>Evaluating the efficacy of Alflibercept Injections in DME Following Treatment With Bevacizumab and Ranibizumab
Alflibercept: Intravitreal Injection</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="43" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin Dependency (Independent/Dependent)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Independent</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Dependent</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetic Retinopathy (Proliferative/Non-Proliferative)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Proliferative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Proliferative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Average Anti-VEGF Injections Received Prior to Baseline</title>
          <units>injections</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.5" lower_limit="6" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Visual Acuity</title>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="36" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Optical Coherence Tomography (OCT) Central Subfield Thickness (CST)</title>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="459" lower_limit="310" upper_limit="721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eyes with Prior Macular Laser</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eyes with Prior Panretinal Photocoagulation (PRP)</title>
          <units>Eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction in Macular Edema</title>
        <description>Reduction in macular edema measured as
Proportion of eyes with baseline SD OCT CST &gt;350 um demonstrating &gt;15% reduction at week 52 from baseline
Proportion of eyes that demonstrate SD OCT CST &lt;305um (males) and &lt;290 um (females) at week 52 from baseline</description>
        <time_frame>52 weeks from baseline</time_frame>
        <population>Answered to the query of PRS review</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Single Arm Trial</title>
            <description>Evaluating the efficacy of Alflibercept Injections in DME Following Treatment With Bevacizumab and Ranibizumab
Alflibercept: Intravitreal Injection</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Macular Edema</title>
          <description>Reduction in macular edema measured as
Proportion of eyes with baseline SD OCT CST &gt;350 um demonstrating &gt;15% reduction at week 52 from baseline
Proportion of eyes that demonstrate SD OCT CST &lt;305um (males) and &lt;290 um (females) at week 52 from baseline</description>
          <population>Answered to the query of PRS review</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OCT CST &gt;350 um demonstrating &gt;15% reduction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OCT CST &lt;305um (males)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OCT CST&lt;290 um (females)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase 4 Prospective, Nonrandomized, Open Label, Interventional</title>
          <description>Evaluating the efficacy of Alflibercept Injections in DME Following Treatment With Bevacizumab and Ranibizumab
Alflibercept: Intravitreal Injection
Study eyes will receive 5 required initial monthly IAI doses of 2 mg followed by 2q8 IAI for a total of 52 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Heart attack</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Hospitalized for sepsis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization- Low electrolytes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular events</sub_title>
                <description>Hypertension</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Subconjunctival Hemorrhage</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Trace Epiretinal Membrane</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blurry Vision</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Common Cold</sub_title>
                <description>Including Influenzas, sinus infections, upper respiratory infections</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Bladder Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney/Liver Conditions</sub_title>
                <description>Kidney stone, bladder infection</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Volume Overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract Extraction</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Yag Laser Capsulotomy</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size, no control group with continuation of bevacizumab/ranibizumab, 6 mth time point potentially skewed as last IAI at 4 mth due to protocol amendment. Loss of OCT, Fundus, Fluorescein Angiography on 1st 5 pts due to technical error</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Dennis Marcus</name_or_title>
      <organization>Southeast Retina Center</organization>
      <phone>706650061</phone>
      <email>dmarcus@southeastretina.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

